Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: A pilot study

Clinical and Translational Oncology

Volumn 15, Issue 11, 2013, Pages 953-958

  Osman, J ^a   Galli, S ^b   Hanafy, M ^a   Tang, X ^a   Ahmed, A ^c  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Immunohistochemistry; Nestin; Neuroblastoma; VEGF; XIAP

Indexed keywords

NESTIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; X LINKED INHIBITOR OF APOPTOSIS;

ADOLESCENT; ARTICLE; BONE MARROW METASTASIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEUROBLASTOMA; PILOT STUDY; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; BONE MARROW NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; INFANT, NEWBORN; MALE; NESTIN; NEUROBLASTOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84886590644     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1030-4     Document Type: Article

References (27)

1. Escobar MA, Grosfeld JL, Powell RL, West KW, Scherer LR 3rd, Fallon RJ, et al. Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg. 2006;41:377-81. (Pubitemid 43233858)
2. Kuroda T, Morikawa N, Matsuoka K, Fujino A, Honna T, Nakagawa A, et al. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. J Pediatr Surg. 2008;43:2182-5.
3. Wiese C, Rolletschek A, Kania G, Blyszczuk P, Tarasov KV, Tarasova Y, et al. Nestin expression-a property of multi-lineage progenitor cells? Cell Mol Life Sci. 2004;61(19-20):2510-22. (Pubitemid 39586514)
4. Krupkova O Jr, Loja T, Zambo I, Veselska R. Nestin expression in human tumors and tumor cell lines. Neoplasma. 2010;57(4):291-8.
5. Kashkar H. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res. 2010;16(18):4496-502.
6. Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005;6:209.
7. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29(6 Suppl 16):10-4.
8. Russel HV, Hicks J, Okcu MF, Nuchtern JG. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg. 2004;39:1506-11. (Pubitemid 39349733)
9. Airoldi I, Cocco C, Morandi F, Prigione I, Pistoia V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother. 2008;57(4):541-8. (Pubitemid 351170537)
10. Jakovljević G, Culić S, Stepan J, Bonevski A, Seiwerth S. Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis. J Exp Clin Cancer Res. 2009;28:143.
11. Zhang J, Zheng Y, Wang Y, Tong H. The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas. J Pediatr Hematol Oncol. 2010;32(3): 180-4.
12. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, et al. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multi-kinase inhibitors. Oncogene. 2010;29(20):2938-49.
13. Poomthavorn P, Wong SH, Higgins S, Werther GA, Russo VC. Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells. Endocr Relat Cancer. 2009;16(3):991-1004.
14. Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E, et al. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis. 2011;14(3): 255-66.
15. Zaghloul N, Hernandez SL, Bae JO, Huang J, Fisher JC, Lee A, et al. Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol. 2009;34(2):401-7.
16. Sims TL, Williams RF, Ng CY, Rosati SF, Spence Y, Davidoff AM. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery. 2008;144(2):269-75. (Pubitemid 352010323)
17. Komuro H, Kaneko S, Kaneko M, Nakanishi Y. Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol. 2001;127(12):739-43. (Pubitemid 33079374)
18. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res. 2000;6(5):1900-8. (Pubitemid 30305088)
19. Nowicki M, Konwerska A, Ostalska-Nowicka D, Derwich K, Miskowiak B, Kondraciuk B, et al. Vascular endothelial growth factor (VEGF)-C-a potent risk factor in children diagnosed with stadium 4 neuroblastoma. Folia Histochem Cytobiol. 2008;46(4):493-9.
20. Peiris-Pagès M, Harper SJ, Bates DO, Ramani P. Balance of pro-versus antiangiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth. J Pathol. 2010;222(2):138-47.
21. Becker J, Pavlakovic H, Ludewig F, Wilting F, Weich HA, Albuquerque R, et al. Neuroblastoma progression correlates with down-regulation of the lymphangiogenesis inhibitor sVEGFR-2. Clin Cancer Res. 2010;16(5):1431-41.
22. Murphy AJ, Viero S, Ho M, Thorner PS. Diagnostic utility of nestin expression in pediatric tumors in the region of the kidney. Appl Immunohistochem Mol Morphol. 2009;17(6):517-23.
23. Willoughby V, Sonawala A, Werlang-Perurena A, Donner LR. A comparative immunohistochemical analysis of small round cell tumors of childhood: utility of peripherin and alpha-internexin as markers for neuroblastomas. Appl Immunohistochem Mol Morphol. 2008;16(4):344-8.
24. Thomas SK, Messam CA, Spengler BA, Biedler JL, Ross RA. Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem. 2004;279(27):27994-9. (Pubitemid 38900069)
25. Wu W, He Q, Li X, Zhang X, Lu A, Ge R, et al. Long-term cultured human neural stem cells undergo spontaneous transformation to tumor-initiating cells. Int J Biol Sci. 2011;7(6):892-901.
26. Fulda S. Apoptosis pathways and neuroblastoma therapy. Curr Pharm Des. 2009;15(4):430-5.
27. Mühlethaler-Mottet A, Bourloud KB, Auderset K, Joseph JM, Gross N. Drugmediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL, and RIP. Oncogene. 2004;23(32):5415-25. (Pubitemid 39044052)